KCAS Bio strengthens bioanalytical support for sponsor programs with the NULISA™–ARGO™ HT
The acquisition of the NULISA™–ARGO™ HT system marks a significant milestone for KCAS Bio, elevating their existing technology stack and expanding the ability to support Sponsors across diverse therapeutic areas and drug development phases. To explore the potential of this system, we spoke to Senior Scientific Advisor Christine Bain, who provides insights into the system’s advantages and the strategic opportunities it offers for KCAS Bio’s Sponsors.
Questions:
- What motivated KCAS Bio to acquire the NULISA™–ARGO™ HT system, and how does it complement your existing technology stack?
- How does this platform compare with other technologies in terms of throughput, sensitivity and specificity?
- In which therapeutic areas and drug development phase do you see the greatest potential for Sponsors to benefit from this platform?
- When would you recommend Sponsors utilize pre-built panels and when would they benefit more from a customized assay?
- As one of the select labs offering this platform, how do you see the partnership with Alamar benefiting clients in the future?
Christine Bain, Ph.D.
Senior Scientific Advisor
KCAS Bio
Christine brings more than 25 years of experience in immunology and coordination of immune monitoring studies in the context of clinical trials, with a strong background in oncology and infectious diseases. She oversees scientific affairs from our Lyon, France site, including development of internal programs and collaboration with Sponsors.
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.
In association with:
